Ashley Gallagher is an associate editor for Pharmacy Times.
Why Are Companies Launching Biosimilars With 2 Prices? Julie Reed Explains
Why are companies pricing their adalimumab biosimilars with 2 prices? Can the United States expect more of this pricing strategy for future biosimilar launches? Julie Reed, executive director of the Biosimilars Forum, has the answers.
The Top 3 Policy Initiatives That Could Impact the US Biosimilar Market
Julie Reed, MS, executive director of the Biosimilars Forum, takes a look at the 3 policy initiatives that could have the greatest ramifications for the US biosimilars industry.
Julie Reed: When the US Could See Meaningful Savings From Adalimumab, Ranibizumab Biosimilar Competition
Juliana (Julie) Reed, executive director of the Biosimilars Forum, predicts how long it will take for savings from adalimumab and ranibizumab biosimilar competition to fully manifest and how stakeholders can champion for better market competition for biosimilars.
2 Clarke Drive Cranbury, NJ 08512